Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corporation, filed a Form 4 on September 3, 2026, disclosing the exercise of stock options and the sale of resulting common stock shares pursuant to a pre-arranged Rule 10b5-1 plan.

Key Highlights

  • Option exercise: Mahon exercised 8,300 stock options on September 3, 2026, at an exercise price of $146.03 per share.
  • Shares sold: A total of 8,300 shares of common stock were disposed of across multiple sale transactions on September 3, 2026.
  • Sale price range: Individual sale tranches carried weighted average prices ranging from approximately $478.9344 to $490.885 per share.
  • Remaining ownership: Following all reported transactions, Mahon directly held 45,172 shares of common stock.
  • 10b5-1 plan: The transactions were executed under a pre-arranged plan entered into by Mahon on August 11, 2025.
  • Options remaining: Mahon held 55,840 stock options following the reported exercise, with an expiration date of March 15, 2027.

Details of Mahon's Option Exercise and Share Sales at United Therapeutics

According to the filing, Paul A. Mahon, EVP and General Counsel of United Therapeutics Corp (NASDAQ:UTHR), exercised 8,300 stock options on September 3, 2026. The options carried an exercise price of $146.03 per share and were set to expire on March 15, 2027. The filing notes the options had been exercisable since March 15, 2020. The derivative security was acquired at a reported price of $0.00 per option, and following the exercise, Mahon held 55,840 stock options directly.

The 8,300 shares of common stock acquired through that exercise were then sold across eleven separate tranches on the same date. Per the filing, the sales were executed at weighted average prices, with individual tranches ranging from $478.9344 (1,545 shares) to $490.885 (320 shares). Several tranches note that transactions were executed across multiple trades within price bands, and the filing states that Mahon "undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."

The filing discloses that all transactions were conducted "pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025." After all reported sales, Mahon's direct beneficial ownership in United Therapeutics common stock stood at 45,172 shares. The form was signed by John S. Hess, Jr. under Power of Attorney and dated September 3, 2026.

What Was Disclosed

The filing reports a same-day option exercise and sale of 8,300 shares of United Therapeutics common stock by EVP and General Counsel Paul A. Mahon on September 3, 2026, conducted under a Rule 10b5-1 plan established August 11, 2025.